AnalystsSerge BelangerSerge Belanger's Stock Forecasts
AnalystsSerge Belanger
Analyst Ranking
Top 2%
#74 out of 5290 analysts
Average Return
+19.38%
Win Rate
51%219 out of 428
Risk vs Reward
Poor
Good
Serge Belanger's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Trevi Therapeutics IncTRVI | +426.92% | $2.60 | $13.70 | 2024-12-03 - 2025-12-03 | Buy |
Liquidia CorpLQDA | +337.57% | $14.18 | $62.03 | 2025-05-27 - 2026-05-27 | Buy |
Arcutis Biotherapeutics IncARQT | +297.44% | $2.34 | $9.30 | 2023-11-05 - 2024-11-05 | Buy |
Arcutis Biotherapeutics IncARQT | +297.44% | $2.34 | $9.30 | 2023-11-05 - 2024-11-05 | Buy |
Trevi Therapeutics IncTRVI | +278.35% | $2.91 | $11.01 | 2024-11-07 - 2025-11-07 | Buy |
Serge Belanger Analyst Color
Get additional color on Serge Belanger's coverage of popular stocks
Serge Belanger's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Veradermics IncMANE | 1 | Buy | $136.00 | +48.33% | Initiates Coverage On | 4 days ago |
Oculis Holding AgOCS | 5 | Buy | $38.00 | +238.98% | Maintains | 5 days ago |
Trevi Therapeutics IncTRVI | 23 | Buy | $23.00 | +72.54% | Reiterates | 17 days ago |
Moonlake ImmunotherapeuticsMLTX | 16 | Buy | $30.00 | +67.60% | Maintains | 25 days ago |
Liquidia CorpLQDA | 36 | Buy | $70.00 | +13.18% | Maintains | a month ago |
Xenon Pharmaceuticals IncXENE | 16 | Buy | $78.00 | +50.78% | Maintains | a month ago |
Arcutis Biotherapeutics IncARQT | 26 | Buy | $36.00 | +69.57% | Reiterates | a month ago |
Biocryst Pharmaceuticals IncBCRX | 19 | Buy | $16.00 | +90.25% | Maintains | a month ago |
Cytokinetics IncCYTK | 28 | Buy | $102.00 | +42.70% | Maintains | a month ago |
Ocular Therapeutix IncOCUL | 8 | Buy | $18.00 | +118.18% | Reiterates | a month ago |
Viridian Therapeutics IncVRDN | 22 | Buy | $32.00 | +102.79% | Reiterates | a month ago |
Pacira Biosciences IncPCRX | 29 | Buy | $32.00 | +40.66% | Maintains | a month ago |
Cormedix IncCRMD | 22 | Buy | $15.00 | +79.43% | Maintains | a month ago |
Kalvista Pharmaceuticals IncKALV | 23 | Buy | $36.00 | +33.58% | Maintains | 2 months ago |
Collegium Pharmaceutical IncCOLL | 25 | Buy | $56.00 | +67.77% | Reiterates | 3 months ago |
Esperion Therapeutics IncESPR | 21 | Buy | $5.00 | +59.74% | Maintains | 3 months ago |
Amphastar Pharmaceuticals IncAMPH | 4 | Buy | $30.00 | +51.98% | Maintains | 3 months ago |
Newamsterdam Pharma Co NvNAMS | 11 | Buy | $48.00 | +52.28% | Maintains | 4 months ago |
Heron Therapeutics IncHRTX | 21 | Buy | $3.00 | +602.58% | Maintains | 10 months ago |
Evolus IncEOLS | 16 | Hold | $22.00 | +229.84% | Downgrades | 10 months ago |
Clearside Biomedical IncCLSDQ | 16 | Hold | $45.00 | +10,875.61% | Downgrades | a year ago |
Verrica Pharmaceuticals IncVRCA | 14 | Hold | $120.00 | N/A | Downgrades | 2 years ago |
Revance Therapeutics IncRVNC | 16 | Buy | $12.00 | N/A | Reiterates | 2 years ago |
Dice Therapeutics IncDICE | 1 | Buy | $56.00 | N/A | Reiterates | 3 years ago |
Tricida IncTCDAQ | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Phasebio Pharmaceuticals IncPHASQ | 3 | Hold | N/A | N/A | Downgrades | 4 years ago |
Aerie Pharmaceuticals IncAERI | 5 | Hold | N/A | N/A | Downgrades | 4 years ago |
Clarus Therapeutics Holdings IncCRXTQ | 4 | Hold | N/A | N/A | Downgrades | 4 years ago |
Akebia Therapeutics IncAKBA | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Zogenix IncZGNX | 3 | Hold | N/A | N/A | Downgrades | 4 years ago |
Flexion Therapeutics IncFLXN1 | 1 | Buy | $18.00 | N/A | Maintains | 5 years ago |
Calcimedica IncCALC | 2 | Hold | N/A | N/A | Downgrades | 5 years ago |
Gw Pharmaceuticals PLCGWPH | 3 | Hold | N/A | N/A | Downgrades | 5 years ago |
Zynerba Pharmaceuticals IncZYNE | 1 | Hold | N/A | N/A | Downgrades | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.